High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

• Prif Awduron: Ping Mei (Awdur), C. Eric Freitag (Awdur), Lai Wei (Awdur), Yunxiang Zhang (Awdur), Anil V. Parwani (Awdur), Zaibo Li (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: BMC, 2020-05-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Background Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) i...